There are several differences between our analysis and that used previously to define IRS/COG risk stratification in localized RMS, limiting comparability of the two analyses.2 The prior IRS/COG analysis did not have FOXO1 fusion status available to include in the model, and excluded patients with metastatic disease and included patients with undifferentiated sarcoma, whereas we did the reverse. The gene discussed is FOXO1; the disease is metastatic neoplasm.